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Throughout its complex morphogenesis, the vertebrate skull must at once protect the brain and expand to accommodate its
growth. A key structural adaptation that allows this dual role is the separation of the bony plates of the skull with sutures,
fibrous joints that serve as growth centers and allow the calvarial bones to expand as the brain enlarges. Craniosynostosis,
the premature fusion of one or more calvarial bones with consequent abnormalities in skull shape, is a common
developmental anomaly that disrupts this process. We found previously that a single amino acid substitution in the
homeodomain of the human MSX2 gene is associated with the autosomal dominant disorder craniosynostosis, Boston type.
This mutation enhances the affinity of Msx2 for its target sequence, suggesting that the mutation acts by a dominant
positive mechanism. Consistent with this prediction, we showed that general overexpression of Msx2 under the control of
the broadly expressed CMV promoter causes the calvarial bones to invade the sagittal suture. Here we use tissue-specific
overexpression of Msx2 within the calvarial sutures to address the developmental mechanisms of craniosynostosis and skull
morphogenesis. We demonstrate that a segment of the Msx2 promoter directs reporter gene expression to subsets of cells
within the sutures. In late embryonic and neonatal stages, this promoter is expressed in undifferentiated mesenchymal cells
medial to the growing bone. By P4, promoter activity is reduced in the suture, exhibiting a punctate pattern in
undifferentiated osteoblastic cells in the outer margin of the osteogenic front. Overexpression of Msx2 under the control of
this promoter is sufficient to enhance parietal bone growth into the sagittal suture by P6. This phenotype is preceded by an
increase in both the number and the BrdU labeling of osteoblastic cells in the osteogenic fronts of the calvarial bones. These
findings suggest that an important early event in MSX2-mediated craniosynostosis in humans is a transient retardation ofINTRODUCTION
The vertebrate skull is a complex structure that must
function as a rigid, protective barrier and at the same time
adjust to the expansion of the developing brain. These dual260equirements are met by the separation of the bony plates of
he skull with sutures, fibrous joints that serve as growth
enters and allow the calvarial bones to expand as the brain
nlarges (Cohen, 1993). The growth of the calvarial bones
egins as mesenchymal precursor cells of neural crest origin







and synthesize bone matrix (Cohen, 1993; Couly et al.,
1993). These condensates extend radially outward, eventu-
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261Msx2 Function in Calvarial Developmentally meeting at the presumptive sutures. Growth then
occurs at osteogenic fronts, aggregations of osteoblastic
cells located at the lateral margins of the sutures, in concert
with the growth of the brain. Ablation and transplantation
experiments have shown that the bones and sutures of the
brain case are patterned by the underlying neural tissue
(Benoit and Schowing, 1970). In the final stages of skull
morphogenesis, the dura mater, a three-layered membrane
of neural crest origin lying between the brain and the skull,
can inhibit the growth of bone into the sutures (Opperman
et al., 1993, 1995).
The molecular mechanisms of skull patterning and mor-
phogenesis are poorly understood. A variety of signaling
molecules are known to be expressed in the tissues in-
volved in the patterning of the calvarial bones (Davidson,
1995; Wilkie, 1997), though the developmental functions of
these genes remain unclear. Fgf9 is expressed in the devel-
oping suture, as is the bek isoform of Fgfr2 (Kim et al.,
1998). Bmp2 and Bmp4 are expressed in the osteogenic front
nd Bmp4 in the dura mater and sutural mesenchyme (Kim
t al., 1998). Manipulation of Fgf ligand concentrations in
he murine suture by implantation of Fgf2- or Fgf4-
mpregnated beads can cause both proliferation and differ-
ntiation of osteogenic cells (Iseki et al., 1997; Kim et al.,
998). Implantation of Bmp4-impregnated beads boosts the
umber of sutural cells, but does not affect the proximity of
he calvarial bones (Kim et al., 1998).
Insight into the molecular mechanisms underlying cal-
arial development has also come from human genetics.
utations in several genes are known to cause craniosyn-
stosis, the premature fusion of calvarial sutures with
onsequent abnormalities in skull shape (Wilkie, 1997). A
eature in more than 100 genetic syndromes, craniosynos-
osis occurs in about 1 in 3000 live births (Cohen, 1993;
ilkie, 1997). Apert, Jackson-Weiss, Crouzon, and Pfeiffer
yndromes are caused by activating mutations in FGF
eceptor genes 1, 2, and 3 (Wilkie, 1997), consistent with
ndings that application of FGFs to sutural tissue can
timulate proliferation and differentiation of osteogenic
ells. Saethre–Chozen syndrome is caused by loss-of-
unction mutations in the basic HLH protein twist (Howard
t al., 1997; el Ghouzzi, et al., 1997). We showed that a
utation in MSX2 (P148H), a member of the highly con-
erved Msx homeobox gene family, causes craniosynosto-
is, Boston type (Jabs et al., 1993), an autosomal dominant
isorder affecting a large kindred in the Northeastern
nited States (Warman et al., 1993; Muller et al., 1993).
Despite the identification of specific genetic defects that
ause craniosynostosis syndromes, little is known at the
ell and tissue level about the nature of craniosynostosis
henotypes or the developmental mechanisms that under-
ie them. One general model to account for syndromic
raniosynostosis is that the various mutations affect the
aturation rate of osteogenic cells within the sutures.
vidence in favor of this hypothesis comes from cell culture
tudies demonstrating that increased numbers of osteoblas-
ic cells can be recovered from sutures of individuals
b
Copyright © 1999 by Academic Press. All rightffected with Apert syndrome (Lomri et al., 1998). Addi-
ional support is provided by a recent study showing that
orced expression of Msx genes in calvarial osteogenic cells
etards differentiation, maintaining cells in a proliferative
tate (Dodig et al., 1998). This finding led to the suggestion
hat a transient retardation of osteogenic cell differentiation
ithin the suture might lead to an increased pool of
roliferative osteogenic cells and ultimately to an increase
n calvarial bone growth. However, the extent to which
hese findings apply to calvarial growth and craniosynosto-
is in vivo has not been established.
To evaluate possible effects on osteogenic cell popula-
ions in vivo, and more broadly to investigate the signaling
athways underlying skull morphogenesis, we have taken a
enetic approach focused on Msx2. Msx2 is one of three
elated genes in the murine genome (Davidson, 1995). It is
xpressed at several key sites in the developing skull,
ncluding the neural crest population that gives rise to the
alvarial bones. It is also expressed in the dura mater and in
nderlying neural tissue, both of which have been impli-
ated in the signaling events that pattern the skull and
utures (Opperman et al., 1993; Kim et al., 1998). Homolo-
ous targeting in mice has shown that Msx1 and Msx2 have
leiotropic activities in development, functioning in epi-
helial mesenchymal interactions that underlie the devel-
pment of the skull, teeth, eyes, skin, mammary glands,
nd kidneys (Satokata et al., 1994; Chen et al., 1996;
hippard et al., 1996; R. Maas, personal communication).
sx genes increasingly have been linked to the BMP
athway (Vainio et al., 1993; Ferrari et al., 1998). Epistasis
tudies have shown that expression of the Drosophila msh
ene during neurogenesis is regulated by Dpp (D’Alessio et
l., 1996). The murine Msx1 gene is required for BMP4
utoinduction in the oral mesenchyme (Bei et al., 1995),
nd in Xenopus, Msx1 can rescue phenotypes induced by a
ominant negative BMP receptor (Suzuki et al., 1997).
The dominant nature of the Boston-type craniosynostosis
utation prompted us to use transgenic mice to gain
nsight into the mechanisms of craniosynostosis as well as
he function of Msx2 in calvarial morphogenesis and BMP
ignaling. Previously we created transgenic mice in which
he p148h mutant Msx2 gene was overexpressed under the
ontrol of a CMV (cytomegalovirus) or TIMP1 (tissue inhib-
tor of metalloprotease) promoter. Such mice exhibited
nhanced calvarial bone growth (Liu et al., 1995).
verexpression/misexpression of wild-type Msx2 also cre-
ted this phenotype, consistent with the molecular data
uggesting that the p148h mutation acts by a dominant
ositive mechanism. This phenotype was not characterized
n detail at a histological level; thus the cell types affected
y enhanced Msx2 activity were not identified. Also this
ransgenic model was limited by the rather general expres-
ion patterns of the CMV and TIMP promoters, which made
t difficult a priori to investigate precisely how















































Accordingly, we decided to use the murine Msx2 pro-


















































262 Liu et al.moter to overexpress Msx2 focally and to use such Msx2
ransgenic mice to investigate the cellular and developmen-
al mechanisms of craniosynostosis. Winograd et al. (1997)
also used a portion of the human MSX2 promoter to drive
expression of the human MSX2 gene in transgenic mice.
Such mice apparently did not exhibit craniosynostosis;
however, they died perinatally with neural tube defects,
precluding analysis of postnatal stages.
Here we describe the expression pattern of a murine Msx2
promoter segment in calvarial development. This promoter
directs reporter gene expression to the developing sutures,
including the osteogenic fronts of the calvarial bones. We
show that unlike the MSX2 transgene driven by the human
SX2 promoter, this murine transgene does not result in
ethality, thus enabling us to recover stable lines and
nalyze cranial phenotypes. Overexpression of Msx2 under
he control of this promoter results in enhanced calvarial
one growth. Moreover, this phenotype is associated with
n increase in the number of proliferative, early-stage
steoblastic cells in the osteogenic fronts. These data,
ogether with findings of Dodig et al. (1998) on the effect of
orced expression of Msx2 on osteogenic cell differentiation,
re consistent rather with the view that enhanced expres-
ion of Msx2 transiently inhibits osteoblast differentiation,
resulting in an increase in the osteoblast pool and ulti-
mately in an increase in bone growth.
MATERIALS AND METHODS
Transgene Constructs
A SpeI–NotI fragment, which contains part of the first exon and
minimal promoter of the Msx2 gene, from plB1.6 was subcloned
into pBluescript SK II(2) (Stratagene, La Jolla, CA) to generate
pSK-SN. Subsequently, a 5-kb XhoI–SpeI fragment covering most of
the upstream regulatory sequences for the Msx2 gene was sub-
cloned into the SpeI/XhoI site of pSK-SN to generate pSK-SNNX.
The NotI–XhoI fragment from pSK-SNNX was then moved into
NotI/XhoI sites of pGem11Zf(2) (Promega, Madison, WI) to make
pGem11Zf-NX-#3. To create the coding region for the transgene, a
BssHII2XhoI fragment covering the entire coding region, intron,
and 39 sequences of the Msx2 gene was cloned into the HindIII/
XhoI sites of pSP73 (Promega) to generate pClone17. A SalI–NdeI
fragment that contains the entire first exon and intron was moved
from pClone17 and replaced the KpnI–NdeI fragment of pCRIIc-
Msx2. A SalI site was regenerated as a result. The intron was
hortened to approximately 500 bp by removing a 3.1-kb KpnI
fragment from this plasmid to generate pCRIIWTDKpnI. A PCR
product containing the 39 UTR and polyadenylation signal from the
human MSX2 gene was then cloned into the EcoRI/XhoI site of
pCRIIWTDKpnI to create pCRIIWTDKpnIhpa. To complete the
construction of pMsx2WThpa, the SalI–NotI fragment in
pCRIIWTDKpnIhpa was replaced by the SalI–NotI DNA fragment
from pGem11Zf-NX-#3. For microinjection, the transgene was
freed from vector sequences by cleaving the plasmid with XhoI.
Copyright © 1999 by Academic Press. All rightGeneration of Transgenic Mice and Analysis of
Cranial Phenotypes
Fertilized eggs were obtained from superovulated, 4- to 5-week-
old (C57BL/6J 3 CBA/J)F1 females impregnated by (C57BL/6J 3
BA/J)F1 adult males (The Jackson Laboratory, Bar Harbor, ME).
seudopregnant females for embryo transfer were produced by
atings between CD1 adult females and vasectomized CD1 adult
ales (Charles River, Wilmington, MA). Microinjection and ovi-
uct transfer of injected zygotes was performed as described (Hogan
t al., 1986). Usually, both procedures were performed on the same
ay. The concentration of DNA used for injection was 1 mg/ml.
enotype analysis was carried out as previously described (Liu et
l., 1994).
Fixation and histological analysis of embryonic heads were as
escribed by Liu et al. (1995). To analyze expression of the Msx2
acZ transgene, calvariae were dissected free of brain and skin and
tained as described in Liu et al. (1994).
BrdU Labeling
Conditions for BrdU labeling and detection were adapted from
Silvestrini et al. (1994). Mice were injected intraperitoneally with
00 mg of BrdU per gram of body weight. After 2 h, the animals were
acrificed and heads were fixed and decalcified in 4% paraformal-
ehyde 1 10% EDTA for 24–48 h, depending on the age of the
nimal (older animals required longer times). Heads were dehy-
rated through graded ethanol and embedded in paraffin. Sections
ere cut (5 mm), deparaffinized, and soaked in 3% hydrogen
peroxide in methanol for 10 min. They were washed three times in
PBS and treated with proteinase K (100 mg/ml in 50 mM Tris–HCl,
5 mM EDTA, pH 8.0) for 20 min at 37oC. Subsequently, to
epurinate DNA, sections were incubated in freshly prepared 2 N
Cl for 45 min at room temperature and neutralized in 0.1 M
odium borate (pH 8.5) for 10 min. Sections were then rinsed three
imes in 13 PBST (13 PBS, 0.1% Tween 20). Immunodetection of
rdU was performed with a Zymed HistoMouse Immunostaining
it according to the manufacturer’s instructions.
Histochemical Detection of Alkaline Phosphatase
Deparaffinized sections were washed three times in 13 TBST
103 TBS: 8 g NaCl, 0.2 g KCl, 3g Tris, pH 7.6, in 100 ml; 0.1%
ween 20). This was followed by three washes in 13 NMTT (100
M NaCl, 50 mM MgCl2, 100 mM Tris–HCl, pH 9.5, 0.1% Tween
0). NBT-BCIP (0.34 mg/ml nitroblue tetrazolium salt, 0.175
g/ml 5-bromo-4-chloro-3-indolyl phosphate) staining solution in
3 NMT was applied to sections until a dark purple color appeared.
he reaction was stopped by washing sections with 13 PBS, and
ections were counterstained with Nuclear Fast red. Simultaneous
etection of lacZ and alkaline phosphatase was carried out as
ollows. Calvariae, stripped of skin and brain tissue, were stained in
-gal solution lacking NP-40 and sodium deoxycholate at 37oC for
4–16 h. Stained calvariae were then fixed for 1 to 2 h in 4%
paraformaldehyde, 10% EDTA and subsequently embedded in
paraffin and sectioned. Sections were stained for alkaline phospha-
tase in the presence of NBT–BCIP as described above.
ImmunohistochemistryThe bone sialoprotein rabbit polyclonal antibody was a generous
gift from Dr. Larry Fisher of the NIH (NIDR). The Fgfr2 antibody
s of reproduction in any form reserved.
e to a
c al., 1
263Msx2 Function in Calvarial Developmentwas purchased from Santa Cruz Biotechnology. Primary antibody
was allowed to react with tissue sections of mouse calvariae. A
biotinylated, affinity-purified secondary antibody was then bound
to the primary antibody (Zymed Laboratories, San Francisco, CA).
An HRP-conjugated streptavidin was added as a signal amplifier.
The immunoreactivity was visualized with an AEC chromagen/
substrate system that creates a red deposit. Sections were counter-
stained with hematoxylin.
Cell Counts and Statistical Analysis
Histological sections of the midsagittal suture were visualized
under Nomarski optics. Osteoblastic (alkaline phosphatase posi-
tive) cells in the osteogenic front, which were clearly distinct from
other sutural cells, were counted independently by three different
observers in at least three different sections. These cell counts were
averaged to obtain an overall average for each section and for each
individual mouse. A minimum of three mice were analyzed in each
experimental group. Our test of the statistical significance of the
cell counts took into account the variability between sections and
between mice. An analysis of variance was used to test the effect of
genotype on cell number. We used a standard F test, the denomi-
nator of which was a linear combination of the mean square of the
individual and the mean square of the tissue section, as determined
by the expected mean squares (with the individual and section
taken as random effects and treatment taken as a fixed effect).
FIG. 1. Schematic maps of Msx2 transgenes. A 5.2-kb segment
xpression pattern of the endogenous Msx2 gene was fused either
ontained the two Msx2 exons and a portion of the intron (Bell etEstimates of the mean effect were based on mouse averages;
standard errors were based on the variance components for the
Copyright © 1999 by Academic Press. All rightindividual and section variability. An identical approach was used
to test differences in cell numbers between developmental stages.
RESULTS
An Msx2 Promoter Segment That Directs
Expression to the Developing Skull and Sutures
We showed previously that a construct containing 5.2 kb
of Msx2 59 flanking sequence fused with a lacZ reporter
closely approximates the expression of the endogenous
Msx2 gene (Liu et al., 1994). In four distinct transgenic
lines, this promoter was expressed in a near-identical pat-
tern, demonstrating that it was not subject to strong posi-
tion effects. Here we use this promoter segment to test the
effects of Msx2 overexpression on the development of the
skull (Fig. 1). We first examined the expression of the 25.2
Msx2–lacZ transgene in greater detail in the developing
skull (Fig. 2). Whole mounts of lacZ-stained embryos at
E18–P4 revealed strong staining in the calvarial sutures
(Figs. 2B–2H), delineating the presumptive parietal and
interparietal bones. The anterior boundary of lacZ expres-
sion coincided with the boundary between the parietal and
the frontal bones. At E18 and P0 (newborn) stages, lacZ
e Msx2 promoter shown previously to approximate closely the
lacZ reporter (A) or to an Msx2 minigene (B). The Msx2 minigene
993).of thexpression was absent from two spots on the dorsal surface
that correspond to the fontanels (Figs. 2B and 2C, arrows).














265Msx2 Function in Calvarial DevelopmentFIG. 3. Overexpression of Msx2 causes the parietal bones to grow into the sutural space. The 5.2-kb Msx2 promoter segment was fused
o an Msx2 minigene and injected into mouse zygotes. Two transgenic lines (TG1 and TG2) were analyzed for transgene expression and the
rowth status of the parietal bones. A representative Northern analysis of transgene expression is shown in A. RNA from whole calvaria
f transgenic and littermate control mice was blotted and allowed to hybridize with a probe that recognized both endogenous (1.9 and 2.4
b) and transgenic (1.9 kb) transcripts. 28S ribosomal RNA is shown below. Densitometry (bar graph) revealed that the 1.9-kb band,
epresenting the transgene transcript and one of two endogenous transcripts, was elevated relative to 28S rRNA in both TG1 and TG2 lines
t P0 (newborn) and P6. WT, wild type littermate control; TG, transgenic. B and C show representative images of skulls derived from a
emizygous Msx2 transgenic and a littermate control at postnatal day 6. Skulls were processed for histology and sectioned coronally
hrough the midsagittal suture. Sections were stained with hematoxylin and eosin. Note that in the control skull (B), the parietal bones
ere well apart, while in the transgenic skull (C), the bones invaded the sutural space and overgrew one another.
FIG. 2. Expression of the 25.2-kb Msx2–lacZ transgene in mouse calvaria. (A) Schematic map of murine skull (left) and cross section of
sagittal suture, showing cell populations (right) A, anterior; P, posterior; f, frontal bone; p, parietal bone, ip, interparietal bone; s, sagittal
suture; c, coronal suture, l, lambdoidal suture. Arrows indicate the level of sections shown in E–H. (B–H) Stains for b-galactosidase activity
t E18.5 (B, E), P0 (newborn) (C, F), and P4 (D, G, H). B, C, and D are whole mounts of skulls in dorsal aspect. Note staining in the sagittal,
oronal, and lambdoid sutures. E–H show coronal sections through the midsagittal suture. The sections shown in F, G, and H were stained
or alkaline phosphatase as well as b-galactosidase. The image in H is an enlargement of the boxed region in G. At E18.5 (E), b-galactosidasestain is evident in cells at the medial edge of the osteogenic front, as well as in osteogenic cells above and below the bone. Note, however,
the zone of reduced lacZ expression just medial to the edge of the parietal bone. At the newborn stage, lacZ is expressed in alkaline
phosphatase-positive cells of the osteogenic front (arrows), in fibroblastic cells of the suture, and in periosteal cells. At 4 days postnatal (G,
H), lacZ is detectable in some cells at the medial edge of the osteogenic front (m). Little stain is apparent in the cells of the lateral osteogenic
front (l).









266 Liu et al.To identify sutural cell types expressing the Msx2 lacZ
transgene, we sectioned skulls of a series of Msx2 lacZ
transgenic mice at stages E18.5, P0, and P4 (Figs. 2E–2H).
Selected sections were also stained for alkaline phosphatase
activity (Figs. 2F, 2G, and 2H). Alkaline phosphatase is an
osteogenic cell lineage marker that is first detectable in
preosteoblasts as they make the transition to osteoblasts,
and continues to be expressed through the remainder of
osteoblast differentiation (Aubin et al., 1995). At E18.5,
lacZ staining was present in periosteal cells and in osteo-
blastic cells at the margin of the growing parietal bone, as
well as above and below the parietal bone (Fig. 2E). These
marginal cells compose the osteogenic front, which serves
as a growth center for the bone (Markens, 1975; Johansen et
al., 1982; Decker and Hall, 1985). Intriguingly, a region of
reduced lacZ staining was consistently present in the os-
teogenic front just medial to the bone (Fig. 2E, arrow). By
P0, lacZ staining was detectable in the periosteum, in
fibroblastic cells of the suture, and in osteoblastic cells of
the osteogenic front and adjacent to the bone (Fig. 2F). At
both P0 and P4, costaining for alkaline phosphatase re-
vealed a partial overlap of lacZ and alkaline phosphatase in
osteoblastic cells (Figs. 2F, 2G, and 2H). At P4, lacZ staining
was reduced in the osteogenic front and was detectable in a
punctate pattern in the outer margins of the alkaline
phosphatase-expressing cell population of the osteogenic
front (Figs. 2G and 2H). The spatial pattern of Msx2 lacZ
expression in the suture is consistent with in situ hybrid-
ization data on the expression of the endogenous Msx2 gene
(Kim et al., 1998).
Overexpression of Msx2 Enhances Calvarial Bone
Growth
We fused the 25.2-kb Msx2 promoter fragment with the
full-length mouse Msx2 cDNA bearing a human MSX2
polyadenylation signal (Fig. 1B). This construct was injected
into mouse zygotes, resulting in seven F0 transgenic pups as
judged by Southern analysis with an Msx2 cDNA probe
(data not shown). Grossly, these animals were smaller than
their nontransgenic littermates; one was anophthalmic and
died shortly after birth (not shown). Two F0 animals dis-
layed circling behavior, consistent with a defect in the
estibular system. One of these died before reaching sexual
aturity. Three of the seven F0 animals reached sexual
maturity but did not transmit the transgene, presumably
because it was incorporated mosaically in cells of the F0.
The two remaining F0 transgenics were crossed with
C57BL6 3 CBA)F1 mice to produce F1 hemizygotes. Mat-
ings between Msx2 transgenic hemizygotes revealed that
none of the transgenic pups were homozygotes, suggesting
that homozygosity for the transgene resulted in embryonic
lethality. Examination of midgestation embryos supported
this possibility. Of 12 homozygous transgenic embryos
examined, all 12 exhibited gross abnormalities, including
anophthalmia and exencephaly (Y-H. Liu and R. Maxson,
unpublished observations). The severity of these pheno-
m
o
Copyright © 1999 by Academic Press. All rightypes made it impossible to investigate processes of cal-
arial morphogenesis in homozygotes; therefore we focused
ur analysis on hemizygotes.
Northern analysis was used to verify that the Msx2
ransgene was in fact overexpressed in Msx2 transgenic
hemizygotes (Fig. 3A). RNA from whole calvaria of Msx2
transgenic and littermate control mice at P0 and P6 was
size separated and blotted, and the blot was incubated with
a probe that recognized both endogenous (1.9 and 2.4 kb)
and transgenic (1.9 kb) Msx2 transcripts. Densitometry
showed that relative to 28S ribosomal RNA, the endoge-
nous 1.9-kb transcript increased in amount by approxi-
mately 3-fold in control mice between P0 and P6. Since in
situ hybridization and expression of the Msx2 lacZ trans-
gene showed that Msx2 levels in the osteogenic front and
sutures decline during this interval (Kim et al., 1998), it is
likely that the higher overall level of Msx2 expression
detected by Northern analysis results from increased Msx2
expression in nonsutural tissues. In two independent trans-
genic lines (TG1 and TG2), the 1.9-kb transcript was
elevated 7-fold and 5-fold, respectively, at P0 and 1.8-fold
and 2.8-fold at P6. It is thus clear (i) that Msx2 was
overexpressed in calvarial tissues of Msx2 transgenic mice
and (ii) that the level of overexpression relative to endoge-
nous Msx2 expression was slightly higher at P0 than at P6.
In situ hybridization analysis of Msx2 expression in Msx2-
overexpressing transgenic embryos was consistent with the
Msx2-lacZ pattern and with the in situ hybridization re-
sults of Kim et al. (1998) (data not shown).
In human craniosynostosis syndromes that affect the
sagittal suture, the development of craniosynostosis occurs
in stages. The parietal bones first come into close apposi-
tion, then fuse at one or more sites over the length of the
suture (Cohen, 1993). Fusion typically does not extend over
the whole length of the suture, but occurs at a few sites. We
asked whether Msx2 transgenic mice exhibited a similar
phenotype. An initial histological examination of the su-
tural morphology of Msx2 transgenic mice at P6 revealed
that the parietal bones had invaded the sutural space and
overlapped (Fig. 3C), while in littermate controls, the pari-
etal bones remained apart (Fig. 3B). This phenotype was
observed in two independent transgenic lines (TG1 and
TG2) in a total of 84% of transgenic pups (11/13). Overex-
pression of Msx2 under the control of a segment of the Msx2
promoter was therefore sufficient to cause the parietal
bones to grow into the sagittal suture. The parietal bones
did not fuse, however, indicating a difference between the
human and the murine phenotypes (see Discussion).
Overexpression of Msx2 Causes an Increase in the
Number of Proliferative Osteoblastic Cells in the
Osteogenic Fronts of Calvarial Bones
To investigate the developmental mechanisms underly-
ing the parietal bone growth phenotype in Msx2 transgenicice, we focused first on possible changes in populations of
steogenic cells within the suture. We used the molecular



































































267Msx2 Function in Calvarial Developmentmarkers alkaline phosphatase and bone sialoprotein to
identify early-stage osteoblasts (preosteoblasts) and late-
stage (mature) osteoblasts respectively (Aubin et al., 1995).
We also examined the expression of FGFR2 (bek isoform),
both because it is expressed in the osteogenic front (Iseki et
l., 1997; Kim et al., 1998) and because activating muta-
ions in FGFR2 have a well-documented role in craniosyn-
stosis syndromes (Wilkie, 1997). BrdU incorporation was
sed to assess the proliferation status of sutural cells. We
arried out these studies in line TG1 (Fig. 3).
Grossly, the spatial distribution of alkaline phosphatase
as similar in transgenic and nontransgenic controls (Figs.
A–4C and 4F–4H). In both groups of animals, activity was
rominent in the osteogenic front and was also detectable
n osteoblastic cells above and below the bone. Fgfr2 stain-
ng was detectable in osteoblastic cells in the osteogenic
ront and was particularly intense in cells closest to the
one. It was also present at reduced intensity in sutural
ells outside the osteogenic front (Figs. 4D and 4I). The
patial distribution of Fgfr2 did not change substantially in
sx2 transgenics (Fig. 4I).
In both transgenic and control mice, bone sialoprotein
as expressed in cells of the osteogenic front lateral to the
ip, as well as in the region of osteoid deposition of the
rowing bone (Figs. 4E and 4J). Together with data on the
xpression of the Msx2–lacZ transgene (Fig. 2), these data
how that within the osteogenic front, the Msx2–lacZ
ransgene was expressed predominantly in osteogenic cells
hat were not fully differentiated. The region of alkaline
hosphatase stain medial to osteogenic front was larger in
sx2-transgenic mice than in control animals (compare
igs. 4B and 4G; Figs. 4C and 4H). BrdU incorporation
tudies on the sagittal suture showed that at both P0 and
4, BrdU was taken up predominantly by osteogenic cells
ocated in the osteogenic front and in the periosteum (Figs.
A–5H). There was little incorporation into cells of the
entral portion of the suture. At both P0 and P4, there was
significant enhancement in the number of BrdU-labeled
ells of the parietal bone osteogenic front in Msx2-
ransgenic animals relative to littermate controls.
We quantitated differences between transgenic and non-
ransgenic mice in the numbers of alkaline phosphatase
ALP)-positive cells and BrdU-labeled cells in the osteogenic
ronts at P0 and P4 (Fig. 6). Cells were counted under
omarski optics in serial sections through the sagittal
uture in three or more mice of line TG1. The characteristic
FIG. 4. Influence of Msx2 transgene expression on osteogenic line
f Msx2 transgenic and control mice showing alkaline phosphatas
gainst Fgfr2 (reddish color, D, I) and bone sialoprotein (BSP, E, J). (
A–E) shows controls, the right (F–J) Msx2 transgenics. B and G are
nder differential interference contrast optics at 1003 magnific
hosphatase-expressing cells in the osteogenic fronts (arrows) of tr
ells of the osteogenic front, as well as in osteoblastic cells adjacent to th
f the matrix of the advancing bone (E, J).
Copyright © 1999 by Academic Press. All rightppearance of osteoblastic cells in the osteogenic front
ade it straightforward to carry out such cell counts. At P0,
ontrol mice had an average of 16.6 ALP-positive cells per
steogenic front 6 3.4 (95% confidence interval), while
sx2-transgenic mice had an average of 28 6 4.3 ALP-
ositive cells/osteogenic front. The difference between
hese mean cell numbers is statistically significant (P ,
0.05). By P4, control mice had an average of 17.6 6 3.7
ALP-positive cells/osteogenic front, while Msx2-transgenic
mice had a mean of 26.6 6 4.6 ALP-positive cells/
osteogenic front (P , 0.05). Analysis of transgenic and
control mice at prenatal stages E16.5 and E18.5 showed no
significant differences in cell number per osteogenic front
(not shown). These data show that overexpression of Msx2
enhanced the number of ALP-positive osteogenic cells in
the osteogenic front of the parietal bones at P0 and P4. A
difference was also apparent in BrdU labeling. At P0,
transgenic animals had an average of 3.1 6 1.1 BrdU-labeled
ells, while controls had an average of 0.6 6 0.4 labeled cells
P , 0.05). By P4, there was an average of 11.5 6 2.3
rdU-labeled cells in the osteogenic front of transgenic
ice compared to an average of 5.4 6 1.7 in controls (P ,
.05). We note also that there was a significant increase in
rdU labeling in both transgenic and control groups be-
ween P0 and P4 (P , 0.05) Thus, the proportion of
steogenic front cells that took up BrdU increased during
evelopment in both groups, but was substantially higher at
oth stages in transgenic animals. We conclude that over-
xpression of Msx2 caused an increase both in the number
f alkaline phosphatase-positive cells and in the number of
rdU-labeled cells in the osteogenic front.
DISCUSSION
In an effort to understand the pathophysiology of cranio-
synostosis and the mechanisms that regulate skull morpho-
genesis, we used a segment of the Msx2 promoter to
overexpress Msx2 in specific cell populations in the devel-
oping skull and sutures. We sought to mimic the effect of
the apparently dominant-activating p148h mutation in the
human MSX2 gene in Boston-type craniosynostosis. The
most significant new finding presented here is that Msx2-
transgenic mice exhibit an increased number of prolifera-
tive osteoblastic cells in the osteogenic front in early
postnatal stages. This effect on the osteogenic front is
n the sagittal suture. Images of cross-sections of the sagittal suture
ivity (ALP, blue color, A–H) and immunostaining with antibodies
Images of P0 (newborn) animals; (C–J) images of P4 mice. The left
rgements of the boxed areas in A and F. Sections were visualized
. Note that at both P0 and P4 stages, there are more alkaline
enic mice than in littermate controls. Fgfr2 staining is evident in
e bone (D, I). At P4, bone sialoprotein expression is present in cells
s of reproduction in any form reserved.
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FIG. 5. Cell proliferation in sutural cell populations of Msx2-transgenic mice. BrdU was injected intraperitoneally into Msx2-transgenic
and littermate control mice at P0 (newborn) and P4. Two hours after injection, calvarial tissue was harvested and processed as described
under Materials and Methods. Sections through the midsagittal suture were stained with an antibody against BrdU and counterstained with
hematoxylin. Stained sections were viewed under Nomarski optics. Images of control sutures are shown on the left, transgenic sutures on
the right. B, F, D, and H are higher magnification images of the boxed regions in A, E, C, and G, respectively. Note that at both P0 and P4,
the number of BrdU-labeled cells (arrow) in the osteogenic front is greater in Msx2-transgenic mice than in littermate controls.
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consistent with the view that MSX2-induced craniosynos-
tosis in humans is a result not of premature differentiation
of osteogenic cells but of a transient inhibition of differen-
tiation. More generally, our findings underscore the point
that a perturbation in the timing of proliferation and
differentiation of a given cell population can have profound
consequences on morphogenesis.
Spatiotemporal Pattern of Msx2 Transgene
Expression
Marker analysis defined the pattern of Msx2–lacZ trans-
gene expression relative to the state of differentiation of
osteoblastic cells at the osteogenic front. The location of
cells within the osteogenic front appears to be correlated
with their state of differentiation: the closer the cell to the
bone (i.e., the more lateral), the further along in differentia-
tion. As expected, the terminal differentiation marker, bone
sialoprotein, was detected in the lateralmost cells of the
osteogenic front that were beginning to synthesize the
osteoid matrix. Alkaline phosphatase, which is first ex-
pressed in osteoprogenitor cells as they make the transition
to osteoblasts and continues to be expressed through much
of osteoblast differentiation (Aubin et al., 1995), was
present in histologically osteoblastic cells throughout the
osteogenic front. Fgfr2 was also expressed in the osteogenic
front, consistent with the data of Iseki et al. (1997). A
comparison of the patterns of these marker proteins with
the expression of the 25.2 Msx2–lacZ transgene showed
that the transgene is not detectably expressed in fully
differentiated osteogenic cells, but in less differentiated
(i.e., alkaline phosphatase-positive, bone sialoprotein-
negative) cells of the osteogenic front, as well as in cells
medial to the bone that do not express bone markers. In
later stages (e.g., P4), Msx2–lacZ was expressed in a punc-
tate pattern in cells of the medial osteogenic front. In situ
hybridization analyses of Msx2 expression in the sagittal
suture are consistent with these results (Kim et al., 1998;
our unpublished results), suggesting that within the suture,
as elsewhere in the embryo, the Msx2–lacZ transgene
closely approximates the expression of the endogenous
Msx2 gene (Liu et al., 1994).
Phenotypic Effects of Msx2 Overexpression and the
Developmental Mechanisms Underlying
Craniosynostosis
Since we used the 5.2-kb Msx2 promoter segment to drive
expression of the Msx2 cDNA in transgenic mice, the lacZ
staining pattern defines, to a first approximation, the ex-
pression of the Msx2 cDNA transgene. Consistent with the
expression of the Msx2–lacZ transgene in early-stage osteo-
blasts, we found that overexpression of Msx2 enhanced the
number of alkaline phosphatase-positive cells in osteogenic
fronts of the sagittal suture. This enhancement was evident
at both P0 and P4, but was not seen in embryos at E16.5 or
E18.5 (not shown). TUNEL assays did not detect significant
levels of apoptotic cells in the sutures between E12.5 and P4
in either transgenic or control mice (not shown), suggesting
that a reduction in cell death does not account for the
increase in osteogenic cell number in the osteogenic front.
BrdU labeling revealed that the total number of prolifer-
FIG. 6. Numbers of alkaline phosphatase-expressing and BrdU-
labeled cells in calvarial osteogenic fronts of Msx2 transgenic mice.
Using light microscopy as illustrated in Figs. 4 and 5, we counted
the number of alkaline phosphatase-expressing and BrdU-positive
cells in osteogenic fronts of the midsagittal sutures of Msx2-
transgenic and littermate control mice. A minimum of three mice
were analyzed in each group. For each mouse, approximately seven
serial sections were examined. Shown are the mean numbers of
labeled cells per osteogenic front 6 the 95% confidence intervals.
The statistical analysis is described under Materials and Methods.
WT, wild type (littermate control); TG, Msx2-overexpressing trans-
genic.
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ating cells was higher at both P0 and P4 in Msx2 transgenics
than in controls. The effect of the transgene on BrdU
labeling did not extend over the whole area of Msx2
overexpression (defined by Msx2–lacZ expression), but was
concentrated in the osteogenic front and periosteum, sug-
gesting that Msx2 overexpression was not sufficient to
promote cell proliferation in nonosteoblastic sutural cells.
We showed previously that CMV-promoter-driven over-
expression of Msx2 in the developing skull and sutures
caused the parietal bones to invade the sagittal suture and
overlap (Liu et al., 1995). This phenotype is generally
similar to that produced by overexpression of Msx2 under
the control of its own promoter (Fig. 3). However, a signifi-
cant difference is that CMV-driven overexpression of Msx2
also induced ectopic bone above the parietal bone. This
difference may be a consequence of the more generalized or
higher-level expression of the CMV promoter compared to
the Msx2 promoter (Liu et al., 1995). Taken together, our
results with the CMV and Msx2 transgenes suggest that
overexpression/misexpression of Msx2 is sufficient (i) to
enhance parietal bone growth, (ii) to augment the number of
osteoblastic cells in osteogenic fronts, and (iii) to induce
cells that would not normally form bone to do so (in the
case of the CMV–Msx2 transgene). One interpretation of
these findings is that overexpression/misexpression of
Msx2 has a positive effect on the development of osteoblas-
tic cells from osteoprogenitors (Fig. 7).
An alternative possibility is suggested by the data of
Dodig et al. (1998), who used Msx2 sense- and antisense-
expressing retroviruses to modulate Msx2 expression in
chick calvarial osteoblast cultures. They demonstrated that
upregulated overexpression of Msx2 mRNA throughout the
culture period prevented the decline in Msx2 protein levels
that normally occurs as the cells differentiate. This con-
tinuous, high-level expression of Msx2 prevented osteoblas-
tic differentiation and mineralization of the extracellular
matrix. In contrast, expression of antisense Msx2 RNA
reduced proliferation and accelerated differentiation. These
results indicate that abnormally high levels of Msx2 expres-
sion can impede the final phases of osteoblastic differentia-
tion and are consistent with findings that forced expression
of Msx2 in a myogenic cell line prevents terminal differen-
tiation (Song et al., 1992; Woloshin et al., 1995).
These data provide an attractive hypothesis that explains
our key observations and may also provide insight into the
pathophysiology of Boston craniosynostosis (Fig. 7). Over-
expression of Msx2 in the sutures of transgenic mice may
maintain osteoblastic cells in a proliferative, undifferenti-
ated state longer than normal. This would explain the
increased pool of early-stage osteoblastic cells found in the
osteogenic fronts at both newborn and P4 stages, as well as
our observation of increased BrdU labeling at P0 and P4. A
change in the pattern of Msx2 expression from the rather
generalized pattern in the suture and osteogenic front,
evident in newborn animals, to a more punctate pattern in
the outer margins of the osteogenic front in P4 animals
might then allow differentiation of this increased osteopro-
genitor pool. This would result in enhanced growth of the
parietal bones into the sutural space. In Boston craniosyn-
ostosis, the dominant-activating p148h mutation would,
similarly, cause an increase in the size of the osteoprogeni-
tor population in the osteogenic fronts. The ultimate differ-
entiation of this population, consequent upon a decline in
Msx2 levels in the osteogenic front, would result in the
overlap of calvarial bones. Fusion of the overlapped bones
would occur subsequently through an as yet unknown
mechanism.
While this hypothesis explains much of the data from
Msx2-transgenic mice, it does not explain the presence of
ectopic bone in transgenic mice in which Msx2 expression
is driven by the CMV promoter (Liu et al., 1995). This
phenotype raises the possibility that Msx2 is capable of
initiating a program of osteogenic differentiation when
ectopically expressed in certain populations of calvarial
cells. It is possible that Msx2 has a positive role in the early
stages of osteogenic differentiation, in addition to its appar-
ent ability to inhibit the terminal differentiation of osteo-
blastic cells. It will be interesting to test this prediction by
examining the effect of targeted inactivation of Msx2 on
calvarial cell populations.
To what extent do the phenotypes exhibited by the Msx2
transgenic mice provide a model for Boston-type craniosyn-
ostosis or other craniosynostosis syndromes? Since Boston-
type craniosynostosis is not described in detail histologi-
cally, we cannot compare our results in the mouse directly
with the human pathology. However, other craniosynosto-
sis disorders have been examined in sufficient detail to
allow comparison. Synostosis of the sagittal suture typi-
cally involves localized fusion of the parietal bones at one
or more sites (Cohen, 1993). Adjacent to the sites of bone
fusion, both enhanced growth of bones into sutural space
and enhanced osteoblast activity are usually seen (Cohen,
1993). Further evidence for enhanced osteoblast activity
comes from studies showing that there is a significant
increase in the number of alkaline phosphatase-positive
cells isolable from sutural tissue of individuals affected
with Apert’s syndrome (Lomri et al., 1998). These results
suggest that enhancement of both the growth of calvarial
bones and osteoblast activity accompanies craniosynosto-
sis. That Msx2-transgenic mice show increased calvarial
bone growth and osteoblast activity suggests that these
mice model at least one aspect of the early phases of
craniosynostosis. Why the calvarial bones do not fuse in
such mice is unclear, though bone fusion apparently does
not occur in older wild-type mice, in contrast to humans
(Zimmermann et al., 1998; our unpublished observations).
The later stages of the program of suture development may
therefore differ in mouse and human.
The p148h mutation in human MSX2 behaves genetically
as an autosomal dominant (Warman et al., 1993; Muller et
al., 1993). We showed that this mutation enhances the
binding affinity for DNA (Ma et al., 1996) as well as the
interaction with a putative partner protein, Miz1 (Wu et al.,
1997). Further, overexpression of both mutant and wild-
271Msx2 Function in Calvarial Development




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































type cDNA under the control of the CMV promoter caused
the parietal bones to invade the sutural space (Liu et al.,
1995). These data led us to suggest that the mutation
functions in a dominant-activating manner (Ma et al.,
1996). Our demonstration here that overexpression of the
wild-type Msx2 causes a cranial growth phenotype is con-
sistent with this hypothesis. As expected, increased dosage
of Msx2 in the mouse mimics at least some of the effects of
the apparently activating mutation in humans. We point
out, however, that genetic proof that the p148h mutation
can influence calvarial growth in the mouse will require the
introduction of this mutation into the endogenous Msx2
gene.
Winograd and co-workers used a human MSX2 promoter
segment to overexpress human MSX2 (huMSX2) in trans-
genic mice (Winograd et al., 1997). These mice died perina-
tally with exencephaly, as was the case with our homozy-
gous Msx2-transgenic mice, though they did not exhibit a
craniosynostosis phenotype. However, since we typically
do not detect enhancement of calvarial bone growth until
postnatal day 3 or later, the lack of a comparable phenotype
in the huMSX2 mice may be a result of the failure of these
mice to survive long enough for the phenotype to become
evident. It is not clear why the human MSX2 mice exhib-
ited a more severe neural tube phenotype than our mice.
Neither the level nor the spatial expression pattern of the
human MSX2 transgene was characterized, leaving open the
possibility that they differed significantly from the murine
Msx2 promoter that we used.
The Role of Msx2 in Signaling Pathways That
Regulate Calvarial Morphogenesis
The osteogenic front expresses ligands and receptors of
the Bmp, Fgf, and Shh pathways (Iseki et al., 1997; Kim et
al., 1998). Might overexpression of Msx2 affect one or more
of these pathways? Implantation of FGF-containing beads
in the murine suture promotes both proliferation and dif-
ferentiation of osteogenic cells (Iseki et al., 1997; Kim et al.,
1998). Fgf beads stimulate Msx1 expression but apparently
do not affect Msx2 (Kim et al., 1998). Implantation of beads
containing Bmp4 increases the number of sutural cells and
also activates Msx2 expression (Kim et al., 1998). Although
the cell populations affected by Bmp4 were not identified,
this increase in cell number is reminiscent of our finding of
an increase in osteoblastic cell number in osteogenic fronts
of Msx2-transgenic mice. Msx2 may therefore act down-
stream of Bmp4 to promote proliferation of osteogenic cells
within the suture.
One inconsistency in this view is that implantation of
Bmp4 beads in the suture does not influence the proximity
of calvarial bones (Kim et al., 1998), while in Msx2-
transgenic mice, the parietal bones ultimately invade the
sutural space (Fig. 3). With the caveat that bead implanta-
tions may not accurately recapitulate endogenous develop-
mental mechanisms, these data suggest that the activity of
Msx2 in the suture may extend outside the Bmp pathway.
Epistasis studies in Drosophila have shown that the Msx-
related gene, msh, is also influenced by EGF and hedgehog
signaling (D’Alessio and Frasch, 1996). Enhanced Msx2
activity in the mammalian suture may therefore affect
more than one growth factor pathway.
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